Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines.

Markey K, Asokanathan C, Feavers I.

Toxins (Basel). 2019 Jul 17;11(7). pii: E417. doi: 10.3390/toxins11070417. Review.

2.

Typing complex meningococcal vaccines to understand diversity and population structure of key vaccine antigens.

Rodrigues CMC, Chan H, Vipond C, Jolley K, Harrison OB, Wheeler J, Whiting G, Feavers IM, Maiden MCJ.

Version 2. Wellcome Open Res. 2019 Mar 19 [revised 2019 Jan 1];3:151. doi: 10.12688/wellcomeopenres.14859.2. eCollection 2018.

3.

Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study.

Bryan P, Seabroke S, Wong J, Donegan K, Webb E, Goldsmith C, Vipond C, Feavers I.

Lancet Child Adolesc Health. 2018 Jun;2(6):395-403. doi: 10.1016/S2352-4642(18)30103-2. Epub 2018 Apr 25.

PMID:
30169281
4.

Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, DT and TT glycoconjugate vaccines.

Beresford NJ, Martino A, Feavers IM, Corbel MJ, Bai X, Borrow R, Bolgiano B.

Vaccine. 2017 Jun 16;35(28):3598-3606. doi: 10.1016/j.vaccine.2017.03.066. Epub 2017 Apr 10.

5.

Recent Progress in the Prevention of Serogroup B Meningococcal Disease.

Feavers IM, Maiden MCJ.

Clin Vaccine Immunol. 2017 May 5;24(5). pii: e00566-16. doi: 10.1128/CVI.00566-16. Print 2017 May. Review.

6.

Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward".

Wetzler LM, Feavers IM, Gray-Owen SD, Jerse AE, Rice PA, Deal CD.

Clin Vaccine Immunol. 2016 Aug 5;23(8):656-63. doi: 10.1128/CVI.00230-16. Print 2016 Aug. Review.

7.

Dissection of the function of the RmpM periplasmic protein from Neisseria meningitidis.

Maharjan S, Saleem M, Feavers IM, Wheeler JX, Care R, Derrick JP.

Microbiology. 2016 Feb;162(2):364-375. doi: 10.1099/mic.0.000227. Epub 2015 Dec 16.

PMID:
26678687
8.

Limitations of the rabbit pyrogen test for assessing meningococcal OMV based vaccines.

Vipond C, Findlay L, Feavers I, Care R.

ALTEX. 2016;33(1):47-53. doi: 10.14573/altex.1509291. Epub 2015 Dec 2.

9.

FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression.

Sanders H, Norheim G, Chan H, Dold C, Vipond C, Derrick JP, Pollard AJ, Maiden MC, Feavers IM.

PLoS One. 2015 Oct 14;10(10):e0140345. doi: 10.1371/journal.pone.0140345. eCollection 2015.

10.

An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity.

Norheim G, Sanders H, Mellesdal JW, Sundfør I, Chan H, Brehony C, Vipond C, Dold C, Care R, Saleem M, Maiden MC, Derrick JP, Feavers I, Pollard AJ.

PLoS One. 2015 Sep 21;10(9):e0134353. doi: 10.1371/journal.pone.0134353. eCollection 2015.

11.

Investigation into the Antigenic Properties and Contributions to Growth in Blood of the Meningococcal Haemoglobin Receptors, HpuAB and HmbR.

Bidmos FA, Chan H, Praekelt U, Tauseef I, Ali YM, Kaczmarski EB, Feavers I, Bayliss CD.

PLoS One. 2015 Jul 24;10(7):e0133855. doi: 10.1371/journal.pone.0133855. eCollection 2015.

12.

A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.

Marsay L, Dold C, Green CA, Rollier CS, Norheim G, Sadarangani M, Shanyinde M, Brehony C, Thompson AJ, Sanders H, Chan H, Haworth K, Derrick JP, Feavers IM, Maiden MC, Pollard AJ.

J Infect. 2015 Sep;71(3):326-37. doi: 10.1016/j.jinf.2015.05.006. Epub 2015 May 15.

13.

Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.

Mehta OH, Norheim G, Hoe JC, Rollier CS, Nagaputra JC, Makepeace K, Saleem M, Chan H, Ferguson DJ, Jones C, Sadarangani M, Hood DW, Feavers I, Derrick JP, Pollard AJ, Moxon ER.

PLoS One. 2014 Dec 29;9(12):e115713. doi: 10.1371/journal.pone.0115713. eCollection 2014.

14.

Whole-cell pertussis vaccine potency assays: the Kendrick test and alternative assays.

Xing D, Markey K, Das RG, Feavers I.

Expert Rev Vaccines. 2014 Oct;13(10):1175-82. doi: 10.1586/14760584.2014.939636. Epub 2014 Sep 3. Review.

PMID:
25182836
15.

Phase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage.

Alamro M, Bidmos FA, Chan H, Oldfield NJ, Newton E, Bai X, Aidley J, Care R, Mattick C, Turner DP, Neal KR, Ala'aldeen DA, Feavers I, Borrow R, Bayliss CD.

Infect Immun. 2014 Jun;82(6):2472-84. doi: 10.1128/IAI.01521-14. Epub 2014 Mar 31.

16.

Identification of vaccine antigens using integrated proteomic analyses of surface immunogens from serogroup B Neisseria meningitidis.

Tsolakos N, Brookes C, Taylor S, Gorringe A, Tang CM, Feavers IM, Wheeler JX.

J Proteomics. 2014 Apr 14;101:63-76. doi: 10.1016/j.jprot.2014.02.013. Epub 2014 Feb 21.

PMID:
24561796
17.

Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.

Nagaputra JC, Rollier CS, Sadarangani M, Hoe JC, Mehta OH, Norheim G, Saleem M, Chan H, Derrick JP, Feavers I, Pollard AJ, Moxon ER.

Clin Vaccine Immunol. 2014 Feb;21(2):234-42. doi: 10.1128/CVI.00561-13. Epub 2013 Dec 18.

18.

The distribution and 'in vivo' phase variation status of haemoglobin receptors in invasive meningococcal serogroup B disease: genotypic and phenotypic analysis.

Lucidarme J, Findlow J, Chan H, Feavers IM, Gray SJ, Kaczmarski EB, Parkhill J, Bai X, Borrow R, Bayliss CD.

PLoS One. 2013 Sep 30;8(9):e76932. doi: 10.1371/journal.pone.0076932. eCollection 2013.

19.

Description and nomenclature of Neisseria meningitidis capsule locus.

Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, Frasch CE, Stephens DS, Feavers I, Frosch M, Parkhill J, Vogel U, Quail MA, Bentley SD, Maiden MC.

Emerg Infect Dis. 2013 Apr;19(4):566-73. doi: 10.3201/eid1904.111799.

20.

Use of a molecular decoy to segregate transport from antigenicity in the FrpB iron transporter from Neisseria meningitidis.

Saleem M, Prince SM, Rigby SE, Imran M, Patel H, Chan H, Sanders H, Maiden MC, Feavers IM, Derrick JP.

PLoS One. 2013;8(2):e56746. doi: 10.1371/journal.pone.0056746. Epub 2013 Feb 15.

21.

Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.

Sadarangani M, Hoe JC, Callaghan MJ, Jones C, Chan H, Makepeace K, Daniels-Treffandier H, Deadman ME, Bayliss C, Feavers I, van der Ley P, Pollard AJ.

PLoS One. 2012;7(12):e51045. doi: 10.1371/journal.pone.0051045. Epub 2012 Dec 12.

22.

WHO/Health Canada meeting on regulatory considerations for evaluation and licensing of new meningococcal Group B vaccines, Ottawa, Canada, 3-4 October 2011.

Feavers I, Griffiths E, Baca-Estrada M, Knezevic I, Zhou T.

Biologicals. 2012 Nov;40(6):507-16. doi: 10.1016/j.biologicals.2012.09.008. Epub 2012 Oct 16.

PMID:
23078946
23.

Resolution of a meningococcal disease outbreak from whole-genome sequence data with rapid Web-based analysis methods.

Jolley KA, Hill DM, Bratcher HB, Harrison OB, Feavers IM, Parkhill J, Maiden MC.

J Clin Microbiol. 2012 Sep;50(9):3046-53. doi: 10.1128/JCM.01312-12. Epub 2012 Jul 11.

24.

History of meningococcal vaccines and their serological correlates of protection.

Vipond C, Care R, Feavers IM.

Vaccine. 2012 May 30;30 Suppl 2:B10-7. doi: 10.1016/j.vaccine.2011.12.060. Review.

PMID:
22607894
25.

Refolding, purification and crystallization of the FrpB outer membrane iron transporter from Neisseria meningitidis.

Saleem M, Prince SM, Patel H, Chan H, Feavers IM, Derrick JP.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Feb 1;68(Pt 2):231-5. doi: 10.1107/S1744309111056028. Epub 2012 Jan 27.

26.

The effect of iron availability on transcription of the Neisseria meningitidis fHbp gene varies among clonal complexes.

Sanders H, Brehony C, Maiden MC, Vipond C, Feavers IM.

Microbiology. 2012 Apr;158(Pt 4):869-76. doi: 10.1099/mic.0.054957-0. Epub 2012 Jan 12.

27.

Structural characterisation, stability and antibody recognition of chimeric NHBA-GNA1030: an investigational vaccine component against Neisseria meningitidis.

Martino A, Magagnoli C, De Conciliis G, D'Ascenzi S, Forster MJ, Allen L, Brookes C, Taylor S, Bai X, Findlow J, Feavers IM, Rodger A, Bolgiano B.

Vaccine. 2012 Feb 8;30(7):1330-42. doi: 10.1016/j.vaccine.2011.12.066. Epub 2011 Dec 27.

PMID:
22210226
28.

Establishment of a new human pneumococcal standard reference serum, 007sp.

Goldblatt D, Plikaytis BD, Akkoyunlu M, Antonello J, Ashton L, Blake M, Burton R, Care R, Durant N, Feavers I, Fernsten P, Fievet F, Giardina P, Jansen K, Katz L, Kierstead L, Lee L, Lin J, Maisonneuve J, Nahm MH, Raab J, Romero-Steiner S, Rose C, Schmidt D, Stapleton J, Carlone GM.

Clin Vaccine Immunol. 2011 Oct;18(10):1728-36. doi: 10.1128/CVI.05252-11. Epub 2011 Aug 18.

29.

Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci.

Callaghan MJ, Lewis S, Sadarangani M, Bailey SE, Chan H, Ferguson DJ, Derrick JP, Feavers I, Maiden MC, Pollard AJ.

Infect Immun. 2011 Jul;79(7):2810-8. doi: 10.1128/IAI.01338-10. Epub 2011 Apr 4.

30.

Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.

Sanders H, Feavers IM.

Expert Rev Vaccines. 2011 Mar;10(3):323-34. doi: 10.1586/erv.11.10. Review.

PMID:
21434800
31.

Influence of the combination and phase variation status of the haemoglobin receptors HmbR and HpuAB on meningococcal virulence.

Tauseef I, Harrison OB, Wooldridge KG, Feavers IM, Neal KR, Gray SJ, Kriz P, Turner DP, Ala'Aldeen DA, Maiden MC, Bayliss CD.

Microbiology. 2011 May;157(Pt 5):1446-56. doi: 10.1099/mic.0.046946-0. Epub 2011 Feb 10.

32.

Variation in the Neisseria meningitidis FadL-like protein: an evolutionary model for a relatively low-abundance surface antigen.

Yero D, Vipond C, Climent Y, Sardiñas G, Feavers IM, Pajón R.

Microbiology. 2010 Dec;156(Pt 12):3596-608. doi: 10.1099/mic.0.043182-0. Epub 2010 Sep 3. Erratum in: Microbiology. 2011 Feb;157(Pt 2):616.

PMID:
20817647
33.

Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media.

Tsolakos N, Lie K, Bolstad K, Maslen S, Kristiansen PA, Høiby EA, Wallington A, Vipond C, Skehel M, Tang CM, Feavers IM, Wedege E, Wheeler JX.

Vaccine. 2010 Apr 19;28(18):3211-8. doi: 10.1016/j.vaccine.2010.02.023. Epub 2010 Feb 25.

PMID:
20188677
34.

Variation and molecular evolution of HmbR, the Neisseria meningitidis haemoglobin receptor.

Evans NJ, Harrison OB, Clow K, Derrick JP, Feavers IM, Maiden MC.

Microbiology. 2010 May;156(Pt 5):1384-93. doi: 10.1099/mic.0.036475-0. Epub 2010 Feb 11.

35.

Functional antibody assays.

Feavers I, Walker B.

Methods Mol Biol. 2010;626:199-211. doi: 10.1007/978-1-60761-585-9_14.

PMID:
20099130
36.

Adjuvant effects on antibody titre.

Walker B, Feavers I.

Methods Mol Biol. 2010;626:187-98. doi: 10.1007/978-1-60761-585-9_13.

PMID:
20099129
37.

Choosing isolates for the evaluation of meningococcal protein vaccines.

Feavers I.

Expert Rev Vaccines. 2009 Nov;8(11):1461-3. doi: 10.1586/erv.09.104. No abstract available.

PMID:
19863236
38.

Meningococcal protein antigens and vaccines.

Feavers IM, Pizza M.

Vaccine. 2009 Jun 24;27 Suppl 2:B42-50. doi: 10.1016/j.vaccine.2009.05.001. Epub 2009 May 28. Review.

PMID:
19481315
39.

Epidemiological evidence for the role of the hemoglobin receptor, hmbR, in meningococcal virulence.

Harrison OB, Evans NJ, Blair JM, Grimes HS, Tinsley CR, Nassif X, Kriz P, Ure R, Gray SJ, Derrick JP, Maiden MC, Feavers IM.

J Infect Dis. 2009 Jul 1;200(1):94-8. doi: 10.1086/599377.

40.

Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada.

Feavers I, Knezevic I, Powell M, Griffiths E; WHO Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines.

Vaccine. 2009 Jun 8;27(28):3681-8. doi: 10.1016/j.vaccine.2009.03.087. Epub 2009 Apr 17.

PMID:
19442421
41.

Analysis of outer membrane porin complexes of Neisseria meningitidis in wild-type and specific knock-out mutant strains.

Marzoa J, Abel A, Sánchez S, Chan H, Feavers I, Criado MT, Ferreirós CM.

Proteomics. 2009 Feb;9(3):648-56. doi: 10.1002/pmic.200800486.

PMID:
19137557
42.

A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies.

Uria MJ, Zhang Q, Li Y, Chan A, Exley RM, Gollan B, Chan H, Feavers I, Yarwood A, Abad R, Borrow R, Fleck RA, Mulloy B, Vazquez JA, Tang CM.

J Exp Med. 2008 Jun 9;205(6):1423-34. doi: 10.1084/jem.20072577. Epub 2008 May 26.

43.

Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines.

Russell JE, Urwin R, Gray SJ, Fox AJ, Feavers IM, Maiden MC.

Microbiology. 2008 Apr;154(Pt 4):1170-7. doi: 10.1099/mic.0.2007/014761-0.

44.

Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.

Finney M, Vaughan T, Taylor S, Hudson MJ, Pratt C, Wheeler JX, Vipond C, Feavers I, Jones C, Findlow J, Borrow R, Gorringe A.

Hum Vaccin. 2008 Jan-Feb;4(1):23-30. Epub 2007 Jul 29.

PMID:
17921703
45.

Species status of Neisseria gonorrhoeae: evolutionary and epidemiological inferences from multilocus sequence typing.

Bennett JS, Jolley KA, Sparling PF, Saunders NJ, Hart CA, Feavers IM, Maiden MC.

BMC Biol. 2007 Sep 7;5:35.

46.

Exploring the proteome of meningococcal outer membrane vesicle vaccines.

Wheeler JX, Vipond C, Feavers IM.

Proteomics Clin Appl. 2007 Sep;1(9):1198-210. doi: 10.1002/prca.200700204. Epub 2007 Aug 17.

PMID:
21136768
47.

Role of bacterial endotoxin in chronic heart failure: the gut of the matter.

Charalambous BM, Stephens RC, Feavers IM, Montgomery HE.

Shock. 2007 Jul;28(1):15-23. Review.

PMID:
17510602
48.

Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry.

Vipond C, Wheeler JX, Jones C, Feavers IM, Suker J.

Hum Vaccin. 2005 Mar-Apr;1(2):80-4. Epub 2005 Mar 2.

PMID:
17038831
49.

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, Miller E, Plikaytis B, van Alphen L, Poolman J, Rappuoli R, Danzig L, Hackell J, Danve B, Caulfield M, Lambert S, Stephens D.

Vaccine. 2006 Jun 12;24(24):5093-107. No abstract available.

PMID:
16838413
50.

Functional significance of factor H binding to Neisseria meningitidis.

Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, Tang CM.

J Immunol. 2006 Jun 15;176(12):7566-75.

Supplemental Content

Loading ...
Support Center